Drug Profile
Bacmune - Inmunotek
Alternative Names: Bactek; BACTEK-MV130; Bactek-O; BACTEK-R; Bacterial-polivalent-vaccine-Inmunotek; MV-130Latest Information Update: 18 Apr 2023
Price :
$50
*
At a glance
- Originator Inmunotek
- Class Bacterial vaccines; COVID-19 vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Bacterial infections; Bone and joint infections; COVID-19 pneumonia
- No development reported Bronchiectasis; Bronchospasm
Most Recent Events
- 12 Apr 2023 Phase-III clinical trials in Bone and joint infections in Spain (Sublingual) (EudraCT2022-004192-16)
- 27 Sep 2022 Phase-III development in COVID-19 pneumonia is ongoing in Dominican Republic (Sublingual) (NCT04363814)
- 27 Sep 2022 No development reported - Phase-II for Bronchiectasis in New Zealand (Sublingual)